FILE:JPM/JPM-8K-20071009151917.txt.gz
EVENTS:	Financial Statements and Exhibits
TEXT:
ITEM: Financial Statements and Exhibits
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
 
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
 
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
 
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
 
 
Item 9.01.  Financial Statements and Exhibits
 
(d) Exhibits
 
The following Exhibits are incorporated by reference into the Registration Statement on Form S-3ASR (333-130051) of JPMorgan Chase & Co. (the Registrant) as exhibits thereto and are filed as part of this Current Report.
 
2
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: October 9, 2007
 
3
 
 
 
 
 
 

 
Exhibit 8.1
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
 
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 722 dated October 4, 2007 relating to Lesser Index Principal Protected Notes Linked to the Nikkei 225 Index and
the S&P 500 Index due April 9, 2008 (the Pricing Supplement) to product supplement no. 16-III dated February 9, 2007 relating to Lesser Index Principal Protected Notes Linked to Nikkei 225 Index and the S&P 500 Index (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Short-Term Debt Instruments in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Short-Term Debt Instruments in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 

 
Exhibit 8.2
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 723 dated October 4, 2007 relating to Lesser Index Principal Protected Notes Linked to the Nikkei 225 Index and the Dow Jones EURO STOXX 50 Index due April 9, 2008 (the Pricing Supplement) to product supplement no. 17-III dated January 11, 2007 relating to Lesser Index Principal Protected Notes Linked to the Nikkei 225 Index and the Dow Jones EURO STOXX 50 Index (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Short-Term Debt Instruments in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Short-Term Debt Instruments in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.
 
 
 

 
Exhibit 8.3
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 724 dated October 4, 2007 relating tBearish Knock-Out Buffered Return Enhanced Notes Linked Inversely to the iShares MSCI Emerging Markets Index Fund due October 16, 2008 Pricing Supplement) to product supplement no. 99-I dated October 4, 2007 relating to Bearish Return Enhanced Notes Linked Inversely to the iShares MSCI Emerging Markets Index Fund (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
o
(the 
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  , subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
Capital Gains Tax Treatment in the Pricing Supplement
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  .  By such consent we do not concede that we are an expert for the purposes of the Act.
Capital Gains Tax Treatment in the Pricing Supplement
 
 
 

 
Exhibit 8.4
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 725 dated October 4, 2007 relating to Buffered Return Enhanced Notes Linked to the S&P 500 Index due April 9, 2009 (the Pricing Supplement) to product supplement no. 18-I dated March 16, 2006 relating to Return Enhanced Notes Linked to the S&P 500 Index (the Product Supplement) to a prospectus supplement dated December 1, 2005 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  , subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
Capital Gains Tax Treatment in the Pricing Supplement
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  .  By such consent we do not concede that we are an expert for the purposes of the Act.
Capital Gains Tax Treatment in the Pricing Supplement
 
 
 


